Tiantan vaccinia virus-based vaccine with promising safety provides sustained protection against mpox in non-human primates.

ABSTRACT: The World Health Organization (WHO) has declared the mpox outbreak a public health emergency of international concern (PHEIC). Safe and efficient vaccines against the mpox virus (MPXV) are urgently needed to impede the surge in cases. Here, we report the results of a preclinical study employing different dosing strategies on a vaccine candidate named NTV, obtained via targeted gene deletion in the Tiantan strain vaccinia virus, resulting in a replication-deficient variant. Following optimisation of the NTV immunization dose and confirmation of its protective efficacy against MPXV in a mouse model, we demonstrate that a two-shot NTV regimen in macaques elicits significant neutralizing antibody and cellular immune responses, providing efficient protection against MPXV challenge. Notably, we

SUBMITTER: Zhu L 

PROVIDER: S-EPMC12325645 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature